Reviewing Oncotarget As A Conventional Journal

Oncotarget is a journal that mainly focuses on the morbid condition of the types of cancers and also the rules used for improving the cancer patients. This journal is all regarding the effect of the management programs and also the rules from the patient’s point of view like contentment and life quality.

This journal is all about searching ample proof regarding the therapies – old and new. It usually focuses on the prospective targets for treatment and therapy. It aids in improving the cancer patients in the best possible manner. Oncotarget is also available on Dove Press.

One can have free access to this journal. Oncotarget does the publishing of the papers online in many of the weekly issues. One can get the paper printed whenever he or she wishes. The primary objective of Oncotarget is to facilitate the results in a fast way and try to carry it as far as possible. We strive to enhance the research’s effect in a big way.

This journal occupies a great significance to science. We believe in the fact that life without any disease is important for people. There has been a great success of Oncotarget. This has led to starting of some other sections that are beyond oncology like Aging, Pathology, Microbiology, Neuroscience and Cell death.

There has been an enormous popularity of Oncotarget, and it assists the authors to enhance the effect of their research. Oncotarget can take the papers that are beyond Endocrinology, Cardiology and Cell Biology. Every paper of Oncotarget may get printed on demand. Our basic idea is to share it with a wider audience all around the world. This journal actively assists the researchers to participate and give their contribution to science. We are bent to make a healthy life without any risk of a disease, and it is our primary objective.

A good aspect about this journal is that it covers wider things about oncology. It came into existence in the year 2010. Oncotarget is also known to publish great research papers in studying cancer and oncology. It also boasts in the publishing of articles related to pathology, physiology, and endocrinology. Follow Oncotarget journal on Twitter.

Mikhail Blagosklonny Contributions in Cancer Research

Mikhail Blagosklonny is a researcher and scientists who has keen interests in the study of aging and cancer. His passion and interests began after he obtained his M.D in internal medicine. He went ahead to with his studies at the First Pavlov State Medical University of St Peterburg where he obtained a PhD in experimental medicine and also, cardiology.

Currently, Mikhail Blagosklonny is an oncology professor at the Rosewell Park Cancer Institute, an institution founded to help in the reduction of cancer challenges that patients face each day. Before that, Mikhail Blagosklonny worked at New York Medical College from 2002 to 2009, where he was the associate professor of medicine. He also worked at Ordway Research Institute as the senior scientist. His work experience, research and study in oncology and aging have given him an upper hand in the two fields.

Being a researcher, Mikhail Blagosklonny has used his determination in the formulation of his hypothesis on regarding the role played by TOR signaling in cancer and aging. Mikhail argues that by using rapamycin to cancer patients, they can increase their life expectancy with the drug. He is fully dedicated to his hypothesis and committed to prove his hypothesis right.

In addition to being a professor, Mikhail Blagosklonny is also an editor. He is a proficient and talented editor in chief of Aging, Oncotarget and Cell Cycle journals. Moreover, he also edits for the Cancer Biology and Therapy. His efforts and dedication have also been realized by the board of Cell Death and Differentiation where he is named as one of the editorial board members. He has several publications that he has edited and continues to gain more popularity from the works he has been involved in in science. See:

Mikhail Blagosklonny has made a name for himself in the publication sector. He has over two hundred and seventy published peer reviewed journals. He has gained so much credibility by being cited by other researchers and authors in the medical and scientific field. His continued involvement in research and oncology studies has made him an important scientist within the study of cancer and aging.